September 22, 2014 – Sirona Biochem Corp.
Vancouver, British Columbia – September 22, 2014 –Sirona Biochem Corp. (TSX-V: SBM, FSE: ZSB) launches the next stage of development for its anti-aging compound library. With recent funding from Bpifrance (the French Public Investment Bank) and the district of Haute Normandie, Sirona Biochem’s subsidiary TFChem (France) moves into the next phase of the agreement with the French laboratory Biogalenys.
Biogalenys has been chosen to work with the team of scientists at TFChem to develop the studies on the anti-aging technology. The research will provide preclinical data supporting multiple targeted applications using novel in vitro tests with varying stress conditions and cell types. The purpose is to both validate the compounds, and to satisfy the standard cohort of cosmetic safety studies. The data will then be used to determine the optimal commercial applications and joint venture partners.
“We are excited to be launching this next phase of development with Biogalenys,” said Dr. Howard Verrico, CEO of Sirona Biochem. “Our two companies previously worked together successfully on the skin lightening technology and have maintained an excellent relationship of shared knowledge. The research on these anti-aging compounds is exciting from both scientific discovery and commercial opportunity prospectus.”
Industry analysts predict that the anti-aging marketplace will reach nearly $285 Billion USD by the year 2018.
Biogalenys is a French laboratory (CRO) specialized in studies of transmembrane passage across several models of epithelia. Biogalenys provides, tests according to GLP or not, for active ingredients and chemical compounds and biological assays to serve the pharmaceutical and cosmetic industries. The laboratory designs the studies, conduct assays, completes data interpretation and classifies the absorption potential of drug and compounds, using different models for in-vitro, in-vivo and ex-vivo assays. Biogalenys is involved in several projects (approved by Cosmetic Valley) in research in cosmetic using efficient test with culture cells models. For more information please visit: http://www.biogalenys.com
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
CFO Sirona Biochem Corp.